Generation Bio (GBIO)
(Delayed Data from NSDQ)
$1.32 USD
-0.03 (-2.22%)
Updated Nov 21, 2024 04:00 PM ET
After-Market: $1.31 -0.01 (-0.76%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GBIO 1.32 -0.03(-2.22%)
Will GBIO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for GBIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GBIO
Generation Bio Co. (GBIO) Reports Q3 Loss, Tops Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates
GBIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Generation Bio Co. (GBIO) Reports Q2 Loss, Tops Revenue Estimates
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
Generation Bio Co. (GBIO) Reports Q1 Loss, Tops Revenue Estimates
Other News for GBIO
Generation Bio Co. Reports Q3 2024 Financials and Progress
Optimistic Buy Rating for Generation Bio Driven by mRNA Advances and Strong Financial Position
Generation Bio GAAP EPS of -$0.23, revenue of $7.55M
Hold Rating Maintained for Generation Bio Amid Technological Progress and Timeline Uncertainty
Generation Bio: Hold Rating Due to Positive Developments and Uncertain IND Timelines